Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 89

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Spinal muscular atrophy+1

Not recruiting

Study of Clenbuterol vs Placebo in Adult Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clenbuterol Hydrochloride
  • Sponsor:Azienda Ospedaliera di Padova

Metachromatic leukodystrophy

Not recruiting

Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa
  • Sponsor:Shire Human Genetic Therapies Inc.

Severe myoclonic epilepsy of infancy+1

Not recruiting

Long-Term Safety Study of Fenfluramine Hydrochloride for Seizures in Patients with Dravet or Lennox-Gastaut Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:Zogenix International Limited

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:CLS12311
  • Sponsor:Cellerys AG

Arterial disorder+1

Not recruiting

Study on Cerebrolysin and Sodium Chloride for Patients with CADASIL

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ever Neuro Pharma GmbH

Multiple system atrophy+1

Not recruiting

Study on the Safety and Tolerability of Exidavnemab in Patients with Mild to Moderate Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Exidavnemab
  • Sponsor:BioArctic AB

Obstructive sleep apnoea syndrome

Not recruiting

Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sultiame
  • Sponsor:Vaestra Goetalandsregionen

Amyotrophic lateral sclerosis

Not recruiting

Study on the Safety and Efficacy of ARGX-119 for Adults with Amyotrophic Lateral Sclerosis (ALS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 monoclonal antibody against muscle specific kinase
  • Sponsor:Argenx

White matter lesion

Not recruiting

Study on the Safety and Tolerability of Guanabenz in Children with Vanishing White Matter Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Guanabenz Acetate
  • Sponsor:Amsterdam UMC Stichting

Corticobasal degeneration

Not recruiting

Study on the Effects of Glycerol Phenylbutyrate in Patients with Corticobasal Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glycerol Phenylbutyrate
  • Sponsor:Klinikum rechts der Isar der TU Muenchen AöR

Glioblastoma multiforme

Not recruiting

Study of Berubicin versus lomustine in adult patients with recurrent Glioblastoma Multiforme after first-line treatment failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Cns Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.